BATM Advanced Communications Ltd (LSE:BVC), a London-listed technology innovator, is making headlines with progress in its diagnostics division.
Its NATlab platform, developed by associate company ADOR Diagnostics, has begun pre-clinical validation at Rome’s Lazzaro Spallanzani National Institute for Infectious Diseases. This follows successful trials in Israel, confirming the system’s ability to quickly and accurately identify infectious diseases.
NATlab’s promise lies in its ability to test for multiple pathogens from a single sample in a matter of minutes. Initial evaluations show 97% sensitivity in detecting positive samples, outperforming competitors in both speed and accuracy.
Shore Capital highlighted this milestone, praising BATM’s delivery across core technologies. However, the broker stressed that BATM’s appeal extends far beyond diagnostics.
Valuation and financial strength
The company's financial position underscores its growth ambitions. With $33 million in cash and equivalents at the last update — equivalent to 30% of its market capitalisation — the company boasts an enterprise value of just $74 million. For context, BATM generated $123.8 million in revenue and $9.3 million in adjusted earnings (EBITDA) last year.
ShoreCap remains optimistic about the group’s trajectory as it noted: “Market inflexion points are nearing — presenting a profitable high-growth opportunity to investors. Asset allocation, with business strategy, is focused on growth investment. Commercialisation should see positive operating leverage to results—leading to an increasingly attractive fundamental valuation.”
Let’s unpack what drives this confidence.
Cybersecurity: Leading the charge
The Cyber division is BATM’s crown jewel and a key pillar of its growth strategy. In a landmark move, the company has partnered with a global technology and defence firm to bring its advanced cybersecurity solutions to commercial markets.
These offerings, which include quantum key distribution and next-generation encryption, were previously focused on governmental clients safeguarding critical infrastructure. Now, the commercial launch opens the door to a much larger addressable market.
The partnership provides BATM with global distribution capabilities and marketing resources, ensuring a strong foothold in new markets. The Cyber division is already delivering results, with first-half revenue more than quadrupling year-on-year to $8.3 million.
New contracts, such as a US$2.3 million deal for quantum-ready encryption technology, reinforce the demand for its solutions. The anticipated commercial debut represents a pivotal moment, potentially driving exponential revenue growth.
Networking: Positioned for growth
The Networking division has faced challenges due to a global slowdown in telecommunications spending. Yet, green shoots are suggesting a recovery. BATM continues to secure significant contracts while expanding its innovative Edgility platform, which enables the management of applications and devices at the edge of networks.
Edgility has found favour with high-profile customers like Totalplay, a major telecommunications provider in Mexico, and Cemex, a global building materials leader. These partnerships highlight the platform’s scalability and potential for recurring revenue.
Additionally, Edgility’s designation as an Amazon Web Services Qualified Software Partner boosts its reach, giving BATM access to AWS’s expansive customer base. A stronger second half is expected, underpinned by new orders for carrier ethernet products and continued adoption of Edgility. Investments in mobile backhaul solutions and next-generation products position the division well to capture future demand.
Diagnostics: Groundbreaking innovation
The Diagnostics division continues to show promise, with revenue rising by 8% to $17 million in the first half of 2024. BATM’s MDXlab molecular diagnostics instrument, launched last year, is gaining traction among mid-sized laboratories.
The division’s innovation extends to next-generation sequencing, where its EXTRAlab NGS Prep product is set for commercial launch by year-end. Participation in an EU-funded tuberculosis diagnostics programme further highlights BATM’s commitment to innovation.
ADOR Diagnostics, meanwhile, is advancing the NATlab platform, which is now undergoing pre-clinical trials in Italy. These developments reinforce the division’s position as a leader in molecular diagnostics, with significant potential for long-term growth.
Strategic vision and outlook
BATM’s management is executing a clear strategy focused on high-margin growth areas. Operational improvements, coupled with a disciplined approach to mergers, acquisitions, and divestments, ensure resources are channelled into core divisions.
For 2024, BATM is on track to deliver strong full-year growth. The Cyber division leads the charge, with Networking set to recover and Diagnostics poised for sustained expansion.
The commercialisation of BATM’s cybersecurity solutions represents a transformative moment, significantly broadening its revenue potential. This, combined with advancements in diagnostics and a rebound in telecommunications, positions the company for long-term success.
As ShoreCap noted, BATM’s current valuation does not reflect its substantial upside potential. With multiple inflexion points on the horizon and a robust strategy in place, the group presents an enticing opportunity for investors seeking exposure to high-growth, technology-driven markets.
As always, we caution readers to do their due diligence and to remember this is a risk-reward scenario, not a risk-free bet. Albeit, the BATM team led by Moti Nagar have done a great deal to minimise the potential downside.